Is a clinical biomarker predictive of outcomes with immune checkpoint inhibitor (ICI) therapy in a phase I patient population.Ulka N. Vaishampayan, Amy Weise, Jaswinder Karwa et al.|Journal of Clinical Oncology|2019Cited by 0